STAT
STAT+: Alkermes’ orexin agonist shows potential to treat ADHD in early-stage trial
The drugmaker Alkermes said a therapy called an orexin agonist for the first time showed potential to treat people with ADHD in an early-stage study.
Elaine Chen
Rights: fair use excerpt

---
Elaine Chen · STAT News · Photo: Alkermes
Source & Credit
Reporting and photography credited as noted above. Originally published by STAT News.
Members only
Checking your membership…